P/E at 35.32 vs Industry's 37.45: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount in a High-P/E Sector

Sun Pharmaceutical Industries Ltd trades at a P/E of 35.32, which is approximately 5.7% below the Pharmaceuticals & Biotechnology industry average of 37.45. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. Given the sector’s elevated valuations, driven by innovation and regulatory approvals, this relative discount may reflect concerns over recent operational challenges or competitive pressures. However, the valuation remains elevated compared to broader market averages, signalling that investors still assign a premium to the company’s earnings stream. Previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating? The valuation premium is a key factor in this reassessment.

Performance Across Timeframes: Mixed Momentum Signals

Examining returns over various periods reveals a divergence in momentum. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 15.87% gain, significantly outperforming the Sensex’s 9.54% loss. This outperformance extends to longer horizons, with three-year and five-year returns of 59.43% and 125.86% respectively, dwarfing the Sensex’s 10.31% and 22.81% gains over the same periods. However, the short-term picture is less encouraging. The stock has declined by 0.79% over the last three months, lagging the Sensex’s 5.06% fall, and has also posted a 3.76% loss over the past month versus the Sensex’s 6.02% drop. This suggests a recent loss of upward momentum despite the longer-term strength. The 1-week and 1-day performances also show slight underperformance, with the stock down 0.91% and 0.65% respectively, while the Sensex was down 2.96% and up 0.11%. Is this short-term weakness a temporary correction or a sign of deeper issues? The data invites close scrutiny of recent developments.

Moving Average Configuration: Mixed Technical Signals

The technical setup of Sun Pharmaceutical Industries Ltd reveals a nuanced trend. The stock is trading above its 5-day and 200-day moving averages but remains below the 20-day, 50-day, and 100-day moving averages. This configuration indicates a short-term recovery attempt within a broader consolidation or downtrend phase. The 200-day average support suggests that the long-term uptrend remains intact, but the failure to clear intermediate moving averages points to resistance and potential volatility ahead. The stock’s recent two-day gain of 1.51% and outperformance of the sector by 0.26% today may be early signs of renewed buying interest. Is this a genuine recovery or a dead-cat bounce at the 50 DMA? The moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Performance Snapshot

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution suggests a sector grappling with uneven growth drivers and regulatory challenges. Within this context, Sun Pharmaceutical Industries Ltd’s relative valuation discount and mixed momentum may reflect broader sector headwinds as well as company-specific factors. The stock’s ability to outperform the Sensex over the year despite these challenges is notable, but the recent short-term softness aligns with sector-wide caution. How does this sector performance influence the stock’s outlook? The interplay is critical for investors to consider.

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 67.0. The rating was updated on 3 September 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the data-driven approach highlights the tension between a still-strong long-term performance and recent short-term headwinds. The valuation discount relative to the sector’s P/E and the mixed moving average configuration are key factors in this reassessment. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Conclusion: A Complex Picture of Valuation and Momentum

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation discount to its sector, with strong long-term returns but recent short-term softness. The moving average configuration suggests a tentative recovery within a broader consolidation phase. Sector results are mixed, adding to the complexity of the outlook. The reassessment of the rating from Buy to Hold by MarketsMOJO reflects these nuanced signals. Investors may wish to consider whether the recent momentum shift is a temporary correction or indicative of a more sustained change in trend — what is the current rating for Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →